Evidence map›Paper›PMID 40156276›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls.

Ryan T Muir, Sophie Stukas, Jennifer G Cooper, Andrew E Beaudin, Cheryl R McCreary, Myrlene Gee, Krista Nelles, Nikita Nukala, Janina Valencia, Kristopher M Kirmess and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Moderating effects of plasma glial fibrillary acidic protein along the Alzheimer's disease continuum.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  8. Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ryan T MuirCalgary Stroke Program, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0002-9349-1069
Sophie StukasDepartment of Pathology and Laboratory Medicine, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.
Jennifer G CooperDepartment of Pathology and Laboratory Medicine, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.
Andrew E BeaudinHotchkiss Brain Institute, Departments of Radiology, University of Calgary, Calgary, Alberta, Canada.
Cheryl R McCrearyHotchkiss Brain Institute, Departments of Radiology, University of Calgary, Calgary, Alberta, Canada.
Myrlene GeeDivision of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Krista NellesDivision of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Nikita NukalaClinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Janina ValenciaClinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Kristopher M KirmessC2N Diagnostics, St. Louis, Missouri, USA.
Sandra E BlackL.C Campbell Cognitive Neurology Research Unit, Dr Sandra Black Centre for Brain Resilience and Recovery, and Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, North York, Ontario, Canada.
Michael D HillCalgary Stroke Program, University of Calgary, Calgary, Alberta, Canada.
Richard CamicioliDivision of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Cheryl L WellingtonDepartment of Pathology and Laboratory Medicine, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.
Eric E SmithCalgary Stroke Program, University of Calgary, Calgary, Alberta, Canada.

Funding

Plasma Abeta isoform concentrations in cognitively impaired patients at risk for amyloidosisR44AG059489 · NIA · C2N DIAGNOSTICS, LLC · PI WEST, TIM · 2018 to 2020
$2.0M
Alzheimer SocietyCIHRNIA NIH HHS R44 AG059489
6 · The paper itself

Abstract

introductionCerebral amyloid angiopathy (CAA) is characterized by the deposition of beta-amyloid (Aβ) in small vessels leading to hemorrhagic stroke and dementia. This study examined whether plasma Aβ

methodsPlasma Aβ

resultsForty-five participants with CAA and 47 healthy controls had available plasma. Aβ DISCUSSION: Plasma Aβ HIGHLIGHTS: Participants with CAA had reduced plasma Aβ

Indexed as

Amyloid beta-PeptidesBiomarkersCerebral Amyloid Angiopathytau ProteinsAgedAged, 80 and overFemaleGlial Fibrillary Acidic ProteinHumansMaleMiddle AgedNeurofilament ProteinsPeptide FragmentsAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)BiomarkersGFAP protein, humanGlial Fibrillary Acidic Proteinneurofilament protein LNeurofilament ProteinsPeptide Fragmentstau ProteinsAlzheimer's diseasebeta‐amyloidcerebral amyloid angiopathyglial fibrillary acidic proteinhemorrhagic strokeneurofilament light chainphosphorylated tauplasma biomarkers

Identifiers

PMID40156276
PMCPMC11953569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.